Ignite Creation Date:
2024-05-06 @ 3:51 AM
Last Modification Date:
2024-10-26 @ 11:40 AM
Study NCT ID:
NCT02399943
Status:
COMPLETED
Last Update Posted:
2022-05-16
First Post:
2015-03-23
Brief Title:
A Trial of Trametinib and Panitumumab in RASRAF Wild Type Advanced Colorectal Cancer
Sponsor:
University Health Network Toronto
Organization:
University Health Network Toronto
Study Overview
Official Title:
Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies
Status:
COMPLETED
Status Verified Date:
2022-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase 2 study the second phase in testing a new drug or drug combination to see how useful the combination of two drugs panitumumab and trametinib are in patients with advanced colorectal cancer with KRAS NRAS or BRAF wild type genes that are not mutated
Panitumumab is a drug that is approved by Health Canada for the treatment of advanced colorectal cancer with KRAS wild type Panitumumab works by binding to and blocking the protein epidermal growth factor receptor EGFR from working
Trametinib is a drug that is approved by Health Canada for the treatment of melanoma with a mutation in the BRAF gene Trametinib works by binding to and blocking mitogen-activated protein kinase kinase MEK 1 and MEK2 from working
Previous studies have shown that the combination of panitumumab and trametinib may be more useful in KRAS NRAS or BRAF wild type colorectal cancer
Panitumumab is a drug that is approved by Health Canada for the treatment of advanced colorectal cancer with KRAS wild type Panitumumab works by binding to and blocking the protein epidermal growth factor receptor EGFR from working
Trametinib is a drug that is approved by Health Canada for the treatment of melanoma with a mutation in the BRAF gene Trametinib works by binding to and blocking mitogen-activated protein kinase kinase MEK 1 and MEK2 from working
Previous studies have shown that the combination of panitumumab and trametinib may be more useful in KRAS NRAS or BRAF wild type colorectal cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None